ICER’s report reviews evidence on the comparative clinical effectiveness and value of poly (ADP-ribose) polymerase (PARP) inhibitors for treatment of ovarian cancer.

For questions or additional information, please contact

Interventions of Interest:

  • Rucaparib (Rubraca®, Clovis Oncology)
  • Niraparib (Zejula®, Tesaro, Inc.)
  • Olaparib (Lynparza®, AstraZeneca)

Final Documents

Below you will find the final documents from the policy paper review process: